US Congress House Bill 4494 (Prior Session Legislation)

---

Spectrum: Moderate Partisan Bill (Democrat 4-1)
Status: Introduced on April 28 2014 - 25% progression, died in committee
Action: 2014-05-02 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Regenerative Medicine Promotion Act of 2014 - Requires the Comptroller General to submit to Congress a report identifying all ongoing federal programs and activities regarding regenerative medicine. Directs the Secretary of Health and Human Services (HHS) to establish a Regenerative Medicine Coordinating Council in the Office of the Secretary with duties to include: (1) preparing a national strategy to support research into regenerative medicine and the development of drugs, biological products, medical devices, and biomaterials for use in regenerative medicine; (2) identifying sources of funding for research into regenerative medicine and areas where such funding is inadequate; and (3) making recommendations regarding federal policies to support development and marketing of regenerative medicine products. Authorizes the Secretary, acting through the Director of the National Institutes of Health (NIH), to make grants for: (1) basic or preclinical research into regenerative medicine; (2) research and development of drugs, biological products, medical devices, and biomaterials for use in regenerative medicine; and (3) the making of an investigational new drug application or an investigational device exemption application within four years of receiving such grant. Amends the Public Health Service Act to authorize the Director of NIH to award grants, contracts, or cooperative agreements to accelerate the development of high need cures through the development of medical products and behavioral therapies for use in regenerative medicine. Authorizes the Secretary, acting through the Commissioner of Food and Drugs, to: (1) conduct, support, or collaborate in regulatory research to assist the Food and Drug Administration (FDA) in performing its functions with respect to regenerative medicine; or (2) make grants to fund regulatory research for such purpose.

Regenerative Medicine Promotion Act of 2014

Rep. Diana DeGette [D-CO]	Rep. Chaka Fattah [D-PA]	Rep. Richard Nolan [D-MN]	Rep. Erik Paulsen [R-MN]
Sen. Chris Van Hollen [D-MD]

Date	Chamber	Action
2014-05-02	House	Referred to the Subcommittee on Health.
2014-04-28	House	Referred to the House Committee on Energy and Commerce.

Type	Source
Summary	https://www.congress.gov/bill/113th-congress/house-bill/4494/all-info
Text	https://www.congress.gov/113/bills/hr4494/BILLS-113hr4494ih.pdf